Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Hypoglossal nerve stimulation and upper airway procedures. Main billing specialty: otolaryngology.
Medicare fee-for-service sleep apnea & airway implants cases in the 26 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (12 state-years, 2020–2024): small markets swing, so treat it as rough.
Professional codes (what the surgeon bills): CPT 64582, 64583, 64584, 42145, 41530.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 126 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 3 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Inspire Medical Systems | 118 |
| Nyxoah | 5 |
| Livanova | 3 |
Product codes: MNQ (stimulator, hypoglossal nerve, implanted, apnea). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 90% of the cases CMS names in Texas; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Sinus surgery & balloon dilation | 1,305 | 139,655−2.1%/yr | −2.1%/yr | 173,800 in 2030+3.7%/yr |
| Ear tubes & middle ear surgery | 69 | 8,303−6.6%/yr |
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 12 | 595+24%/yr | +24%/yr | 0.31.3× | 14% | 630 in 2030+0.9%/yr |
| Florida | 17 | 501+55%/yr | +55%/yr | 0.21.0× | 6% | 600 in 2030+3.1%/yr |
| California | 8 | 343+39%/yr | +39%/yr | 0.10.5× | 11% | 410 in 2030+3.1%/yr |
| Pennsylvania | 8 | 263+58%/yr | +58%/yr | 0.20.9× | 0% | 300 in 2030+2.1%/yr |
| Ohio | 7 | 262+60%/yr | +60%/yr | 0.21.1× | 0% | 230 in 2030−2.4%/yr |
| Arizona | 8 | 239+57%/yr | +57%/yr | 0.31.5× | 9% | 180 in 2030−4.4%/yr |
| Georgia | 8 | 238+64%/yr | +64%/yr | 0.31.3× | 6% | 380 in 2030+8.2%/yr |
| Missouri | 11 | 224+173%/yr | +173%/yr | 0.31.7× | 0% | 150 in 2030−6.1%/yr |
| South Carolina | 8 | 218+73%/yr | +73%/yr | 0.31.5× | 0% | 400 in 2030+10%/yr |
| Mississippi | 4 | 204+118%/yr | +118%/yr | 0.52.5× | 0% | 280 in 2030+5.3%/yr |
| Illinois | 5 | 187+137%/yr | +137%/yr | 0.10.6× | 0% | 160 in 2030−2.3%/yr |
| North Carolina | 6 | 178+96%/yr | +96%/yr | 0.20.8× | 0% | 270 in 2030+7%/yr |
| Iowa | 6 | 171+55%/yr | +55%/yr | 0.41.8× | 36% | 140 in 2030−3.5%/yr |
| Alabama | 3 | 154+128%/yr | +128%/yr | 0.31.6× | 0% | 140 in 2030−1.5%/yr |
| Louisiana | 5 | 148+58%/yr | +58%/yr | 0.31.7× | 0% | 150 in 2030−0.3%/yr |
| New York | 2 | 146+38%/yr | +38%/yr | 0.10.4× | 19% | 160 in 2030+1.2%/yr |
| Indiana | 3 | 142+50%/yr | +50%/yr | 0.20.9× | 9% | 190 in 2030+4.8%/yr |
| Utah | 3 | 142+112%/yr | +112%/yr | 0.63.0× | 0% | 80 in 2030−8.9%/yr |
| Virginia | 4 | 141+51%/yr | +51%/yr | 0.10.6× | 11% | 190 in 2030+5.4%/yr |
| Tennessee | 4 | 136+52%/yr | +52%/yr | 0.20.9× | 0% | 200 in 2030+6.7%/yr |
| Colorado | 3 | 136+11%/yr | +11%/yr | 0.31.3× | 0% | 110 in 2030−3.7%/yr |
| Kansas | 5 | 135+70%/yr | +70%/yr | 0.31.6× | 0% | 140 in 2030+0.8%/yr |
| Massachusetts | 2 | 127+63%/yr | +63%/yr | 0.10.6× | 0% | 110 in 2030−2.2%/yr |
| Oklahoma | 4 | 126+26%/yr | +26%/yr | 0.31.2× | 0% | 180 in 2030+5.9%/yr |
| Kentucky | 3 | 122+0.3%/yr | +0.3%/yr | 0.31.2× | 0% | 70 in 2030−7.9%/yr |
| Nebraska | 2 | 105+149%/yr | +149%/yr | 0.41.9× | 19% | 90 in 2030−2.5%/yr |
| 8,360 in 2030+0.1%/yr |
| Cochlear implants | 114 | 3,948+5.5%/yr | +5.5%/yr | 5,240 in 2030+4.8%/yr |
In 2025, 17 companies reported engagement with surgeons in the covered states worth $5.8M in consulting, speaking, meals and travel tied to these products, about $39K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 18 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.